Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > G12C/G12V KRAS mutation in PC & CRC patients respond to Pela

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 24, 2023 10:44am

135 Views

Post# 35651193

RE:RE:G12C/G12V KRAS mutation in PC & CRC patients respond to Pela

An added benefit is that G12D and G12V KRAS mutations can be used as biomarkers to identify PC & CRC patients using next generation and single-cell sequencing.

https://nanocellect.com/blog/next-generation-sequencing-and-single-cell-technology-whats-the-difference/#:~:text=However%2C%20one%20easy%20distinction%20is,DNA%20or%20RNA%20sequencing%20analysis).

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec